Does Priority Health Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is a biologic RANK-L inhibitor approved by the FDA in June 2010 for several bone-loss conditions. It works differently from bisphosphonates: it blocks osteoclast formation rather than impairing osteoclast function, which produces a distinct antifracture mechanism that can be useful when bisphosphonates fail or are contraindicated. The drug is administered as a 60 mg subcutaneous injection every six months, typically in a clinician's office rather than at home.

The primary FDA-approved indications include postmenopausal osteoporosis in women at high fracture risk, osteoporosis in men at high fracture risk, glucocorticoid-induced osteoporosis, and bone loss associated with hormone-ablation therapy in prostate or breast cancer patients [1]. The FDA label specifies that "high fracture risk" generally means a T-score at or below -2.5 or a prior osteoporotic fracture [1].

The key FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced the relative risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months [2]. These figures are cited in virtually every payer prior-authorization policy as the clinical basis for coverage. Priority Health's medical and pharmacy policies draw on the same published evidence base when setting their coverage criteria [2].

Prolia is not interchangeable with Xgeva (also denosumab, but at a different dose and indication). Payers, including Priority Health, treat them as separate products with separate coverage policies. Submitting a Prolia claim under a Xgeva authorization, or vice versa, will result in an automatic denial [1].

How Priority Health Formulary and Tier Placement Affects Your Cost

Priority Health places Prolia on a specialty or non-preferred brand tier in most of its commercial, Medicare Advantage, and Medicaid managed-care plans. Tier placement directly controls your cost-sharing responsibility.

On a commercial plan with a three-tier formulary, Prolia typically lands on Tier 3 (preferred brand), carrying a coinsurance of 20 to 40% after the deductible. On a four- or five-tier formulary, it often falls on Tier 4 (non-preferred brand or specialty), where coinsurance can reach 30 to 50% per injection. Given Prolia's list price of approximately $1,400 per dose, a 40% coinsurance equals $560 out-of-pocket per injection, or $1,120 per year before any manufacturer savings card applies [3].

Medicare Advantage plans administered by Priority Health are subject to CMS formulary rules. Under Medicare Part B, Prolia is generally billed as a physician-administered drug (J0897), not under Part D, meaning the coinsurance structure follows Part B cost-sharing (typically 20% after the Part B deductible of $240 in 2024) rather than a pharmacy tier structure [4]. Patients with a Medigap supplement that covers Part B coinsurance may owe nothing out-of-pocket.

Medicaid members in Michigan who receive care through Priority Health's Medicaid managed-care plan may find Prolia covered with minimal or zero cost-sharing if prior authorization criteria are met, because Michigan Medicaid covers denosumab under its preferred drug list [5].

Always pull the current Summary of Benefits and Coverage (SBC) or the actual formulary PDF from Priority Health's member portal before assuming a tier. Formularies change each January 1, and mid-year tier changes are possible after a 60-day notice period as permitted under ACA rules [6].

Prior Authorization Requirements for Prolia Under Priority Health

Prior authorization (PA) is required for Prolia in essentially every Priority Health plan. The PA process exists because Prolia is a high-cost specialty biologic with a defined clinical population, and payers use PA to confirm that cheaper first-line agents have been tried or are truly contraindicated.

To obtain PA approval, your prescribing clinician typically must document the following for Priority Health:

A confirmed diagnosis of osteoporosis based on dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or lower at the lumbar spine or femoral neck, OR a documented fragility fracture [7]. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) defines a fragility fracture as one occurring from a fall from standing height or less [8].

Step therapy compliance, meaning the patient has completed at least three to six months of an oral bisphosphonate such as alendronate 70 mg weekly or risedronate 35 mg weekly, unless there is a documented contraindication or intolerance [9]. Contraindications that Priority Health typically accepts include esophageal abnormalities, inability to remain upright for 30 minutes, renal impairment with estimated GFR <35 mL/min/1.73 m², and significant GI intolerance documented in office notes [10].

A prescribing physician who is, or has consulted with, an endocrinologist, rheumatologist, or other specialist familiar with metabolic bone disease is often required for initial PA approval, though some plans accept a primary care physician's attestation.

Renewals (continuation PAs) generally require documentation of clinical response, such as a stable or improved DXA T-score, absence of new fractures, and absence of serious adverse events including hypocalcemia or atypical femur fracture [11].

The PA form must be submitted by the prescribing clinician, not the patient. Most Priority Health PA requests are reviewed within 72 hours for standard requests and 24 hours for urgent or expedited requests under Michigan managed-care regulations [12].

Step Therapy: The Bisphosphonate-First Requirement Explained

Step therapy is the single most common reason Prolia prior authorization requests are initially denied. Priority Health, like most commercial insurers, requires that a patient try and fail a preferred bisphosphonate before a biologic RANK-L inhibitor is approved. This is not arbitrary: oral bisphosphonates such as alendronate reduce vertebral fracture risk by approximately 47% in high-risk patients and cost as little as $4 per month as a generic [13].

The step therapy requirement is waivable under Michigan's step therapy law (MCL 550.1473), which took effect in 2018. This law requires insurers, including Priority Health, to grant a step therapy exception when any of the following apply: the required drug is contraindicated, the required drug is clinically ineffective for the patient's condition, the patient previously tried the required drug and it caused an adverse event, or adherence to step therapy would cause clinically significant harm [12].

To invoke the exception, the prescribing clinician must submit a written exception request with supporting clinical documentation. Acceptable documentation includes office visit notes describing bisphosphonate intolerance, pharmacy dispensing records showing the patient filled and used the bisphosphonate, and a specialist's letter explaining the clinical rationale for skipping to Prolia [8].

Patients who cannot tolerate oral bisphosphonates due to GI issues have an additional option: intravenous zoledronic acid (Reclast, 5 mg once yearly), which Priority Health also covers at a lower tier than Prolia and which does not require the 30-minute upright restriction. Some PA reviewers will ask whether IV zoledronic acid was considered before approving Prolia. If the patient has renal impairment with GFR <35 mL/min, both oral bisphosphonates and IV zoledronic acid become contraindicated, which typically satisfies step therapy exception criteria on its own [10].

What Happens After a Prolia Coverage Denial

Denial of a Prolia PA request is not the end of the road. Under the ACA and Michigan managed-care rules, Priority Health must provide a written denial with the specific clinical reason, and the patient and prescriber have the right to appeal.

The internal appeal must be filed within 180 days of the denial notice for most Priority Health commercial plans. For Medicare Advantage plans, the timeline is 60 days from the denial date [4]. An expedited internal appeal, which Priority Health must resolve within 72 hours, is available when the standard timeline would seriously jeopardize the patient's health.

Grounds for a successful internal appeal typically include: new clinical documentation not present at initial review, a letter of medical necessity from a board-certified endocrinologist or rheumatologist, peer-reviewed literature supporting Prolia for the specific clinical scenario, and documentation of failed step therapy or a valid step therapy exception under Michigan law [12].

If the internal appeal is denied, an external independent medical review (IMR) is available. In Michigan, the Department of Insurance and Financial Services (DIFS) oversees external review for commercial plans. External reviewers overturn insurer decisions in a meaningful proportion of specialty-drug cases, with some analyses finding reversal rates near 40 to 50% for biologics when strong clinical documentation is submitted [6].

Medicare Advantage members have a separate five-level appeal process: redetermination by Priority Health, reconsideration by a Qualified Independent Contractor, ALJ hearing, Medicare Appeals Council review, and federal district court [4].

Real-World Cost Scenarios With and Without Coverage

The difference in patient cost between approved coverage and no coverage is dramatic. Consider three scenarios based on a patient receiving two Prolia injections per year at a list price of $1,400 per injection ($2,800/year):

Scenario 1: Commercial plan, Tier 4 to 40% coinsurance, $3,000 deductible met. Patient owes 40% of $2,800, or $1,120 per year. Amgen's Prolia Co-pay Assistance Program may reduce this to as little as $25 per dose for eligible commercially insured patients, bringing annual out-of-pocket to $50 [3].

Scenario 2: Medicare Part B, 20% coinsurance, Medigap Plan G. Medigap Plan G covers 100% of Part B coinsurance after the Part B deductible, so the patient may owe $0 per injection after the $240 annual deductible is met [4].

Scenario 3: No coverage, uninsured or denied PA. Patient pays full list price of approximately $2,800 per year. Amgen's patient assistance program (Amgen SupportPlus) provides free Prolia to patients who meet income criteria, generally at or below 500% of the federal poverty level [3]. Applying takes 2 to 4 weeks; injections cannot be delayed during the application window, so planning ahead matters.

Alternatives Covered at Lower Tiers by Priority Health

If Prolia coverage is denied and appeals are unsuccessful, Priority Health covers several alternatives that may be more accessible:

Alendronate sodium 70 mg weekly is available as a generic at Tier 1 or Tier 2 on virtually every Priority Health formulary, with a copay often under $10 per month [9]. The FIT trial (N=2,027) showed a 47% reduction in vertebral fractures and a 51% reduction in hip fractures at 36 months in women with prior vertebral fracture [13].

Risedronate 35 mg weekly is another Tier 1, 2 generic option. The VERT-MN trial (N=1,226) demonstrated a 41% reduction in new vertebral fractures over three years [14].

Zoledronic acid 5 mg IV yearly (Reclast) is typically on a mid-tier formulary position and is administered in-office once per year. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fracture risk and a 41% reduction in hip fracture risk at 36 months [15].

Raloxifene 60 mg daily is a selective estrogen receptor modulator covered at Tier 2 in many plans, though it only reduces vertebral fracture risk (50% relative risk reduction in the MORE trial, N=7,705) without a demonstrated hip fracture benefit [16].

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents reserved for severe osteoporosis or very high fracture risk. Both require PA and are typically more expensive than Prolia on a per-year basis; they are not automatic substitutes if Prolia is denied [17].

Clinical Monitoring Requirements That Support Continued Coverage

Insurers including Priority Health often require evidence of ongoing clinical monitoring to approve continuation PAs. Bone-density monitoring with DXA is recommended every one to two years during treatment per the American Association of Clinical Endocrinology (AACE) 2020 guidelines [7]. Serum calcium must be checked before each Prolia injection because denosumab can cause clinically significant hypocalcemia, particularly in patients with vitamin D deficiency or renal impairment [11].

Pre-injection labs that Priority Health may request as part of a renewal PA include: serum calcium (normal range 8.5 to 10.2 mg/dL), 25-hydroxyvitamin D (target 40 to 60 ng/mL per endocrinology guidelines), and estimated GFR to confirm renal safety [10]. Patients should take calcium 1,000, 1 to 200 mg/day and vitamin D 800, 1 to 000 IU/day as recommended by the National Institutes of Health Office of Dietary Supplements while on Prolia [18].

One key clinical point that many patients miss: stopping Prolia abruptly carries a documented rebound risk. The FREEDOM Extension study and subsequent case series have shown that discontinuing denosumab without transitioning to a bisphosphonate can trigger rapid bone loss and an elevated risk of multiple vertebral fractures within 12 to 18 months of the last injection [19]. This rebound phenomenon supports the medical necessity argument for continued coverage, and prescribers should document this risk explicitly in renewal PA letters.

How to Check Your Specific Priority Health Plan's Prolia Coverage

The fastest way to confirm your current coverage is to use three sources simultaneously. First, log in to the Priority Health member portal at priorityhealth.com and search the formulary tool for "denosumab" or "Prolia." Second, call the Priority Health pharmacy services line (the number on the back of your member ID card) and ask for the specific prior authorization criteria document for Prolia under your plan ID. Third, ask your prescribing clinician's office to run a real-time formulary check through their electronic health record system or through Amgen's AccessProlia reimbursement support line.

If your plan is employer-sponsored, your HR benefits administrator can provide the plan's Summary Plan Description, which legally governs coverage, regardless of what the online formulary tool shows [6]. Self-funded employer plans are not subject to Michigan state insurance mandates, including the step therapy exception law, so the appeal process may differ [12].